3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Lung Neoplasms
2
Kidney Neoplasms
2
Adenocarcinoma Of Esophagus
2
Uterine Cervical Neoplasms
1
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Recurrence
1
Ovarian Neoplasms
1
Metastatic Urothelial Cancer
1
Melanoma
1
Lung Diseases
1
Glioblastoma
1
Esophageal Neoplasms
1
Erythrocytosis, Familial, 4
1
Cholangiocarcinoma
1
Advanced Solid Tumors
1
Advanced Non-Small Cell Lung Cancer
1
Interventions
pembrolizumab
6
avelumab
6
Nivolumab
5
Specimen Handling
4
Magnetic Resonance Spectroscopy
3
Biopsy
3
prednylidene
2
lutetium Lu 177 dotatate
2
deltacortene
2
Prednisone
2
Ipilimumab
2
CTLA-4 Antigen
2
talimogene laherparepvec
1
lenvatinib
1
fludarabine phosphate
1
fludarabine
1
decitabine and cedazuridine drug combination
1
cemiplimab
1
aldesleukin
1
Tacrolimus
1
Sirolimus
1
Saline Solution
1
Radiotherapy
1
Radiosurgery
1
MAPRE1 protein, human
1
Lutetium-177
1
Laparoscopy
1
Exercise Test
1
Cyclophosphamide
1
Axitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Merkel Cell
×
zimberelimab
×
90 days
×
Clear all
No trials found.